Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients

AIDS Patient Care and STDs

Volumn 25, Issue 7, 2011, Pages 395-402

  Merchante, Nicolás ^a   López Cortés, Luis F ^b   Delgado Fernández, Marcial ^c   Ríos Villegas, Maria J ^d   Márquez Solero, Manuel ^e   Merino, Dolores ^f   Pasquau, Juan ^g   García Figueras, Carolina ^h   Martínez Pérez, Maria Angeles ⁱ   Omar, Mohamed ^j   Rivero, Antonio ^k   MacÍas, Juan ^a   Mata, Rosario ^a   Pineda, Juan Antonio ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^h Hospital del SAS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j Unidad de Enfermedades Infecciosas   (Spain)

^k HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOSAMPRENAVIR PLUS RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIVER ENZYME;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; RNA, VIRAL; SULFONAMIDES;

EID: 79959813230     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0109     Document Type: Article

References (30)

1. Bonacini M. Liver injury during highly active antiretroviral therapy: The effect of hepatitis C coinfection. Clin Infect Dis 2004;38:S104-108. (Pubitemid 38328172)
2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/ HCV-coinfected patients. J Viral Hepat 2007;14:371-386. (Pubitemid 46744053)
3. Macías J, Mallolas J, López-Cortés L, et al. Liver safety of regimens including two nucleoside analogs plus efavirenz, nevirapine or one ritonavir-boosted protease inhibitor in HIV-infected drug-na?̈ve patients with chronic hepatitis C [Abstract P091]. In: Abstracts of the 10th International Congress on HIV and Drug Therapy in HIV Infection, Glasgow, Scotland: November 2010.
4. Palacios R, Vergara S, Rivero A, et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials 2006;7:319-323. (Pubitemid 46164966)
5. Pineda JA, Santos J, Rivero A, et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008; 61:925-932. (Pubitemid 351426080)
6. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C Virus coinfection. Clin Infect Dis 2005;40:588-593. (Pubitemid 40270230)
7. Macías J, Orihuela F, Rivero A, et al. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus-co-infection and preexisting fibrosis. J Antimicrob Chemother 2009;63:178-183.
8. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006;368:476-482. (Pubitemid 44160731)
9. Norris D, Patel L, Rizzardini G, et al. Efficacy and safety of fosamprenavir/ritonavir (FPV/r) BID or lopinavir/ritonavir (LPV/r) BID in antiretroviral treatment-naive subjects coinfected with hepatitis B (HBV) or C (HCV) and HIV (The KLEAN Study) [Abstract MOPEB059]. In: Abstracts of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007.
10. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004;18:1529-1537.ART (Pubitemid 39037477)
11. DeJesus E, Gladysz A, Vera J, et al. Long Term Safety in HCV/HBV Co-infected Na?̈ve Adults Treated with Fosamprenavir/ Ritonavir [Abstract TuPe1.1C03]. In: Abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil: July 2005.
12. Carosi G, Lazzarin A, Stelbrink H, et al. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviralna? ̈ve HIV-1-infected adult subjects. HIV Clin Trials 2009; 10:356-367.
13. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011;1-174. www.aidsinfo .nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed March 5, 2011).
15. Pérez-El?́as MJ, Morellon ML, Ortega E, et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother 2009;53:5185-5196.
16. Hicks CB, DeJesus E, Sloan LM, et al. Comparison of oncedaily fosamprenavir boosted with either 100 or 200 mf or ritonavir, in combination with abacavir/lamivudine: 96 weeks results from COL100758. AIDS Res Hum Retroviruses 2009;25:395-403.
17. Mira JA, Macías J, Girón-González JA, et al. Incidence and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006;58:140-146. (Pubitemid 44294997)
18. Nuñ ez M, R?́os P, Mart?́n-Carbonero L, Pérez-Olmeda M, González-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002;30:65-68. (Pubitemid 34506688)
19. Torti C, Lapadula G, Puoti M, et al. Influence of genotype 3 hepatitis coinfection on liver enzyme elevation in HIV-1- positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort. J Acquir Immune Defic Syndr 2006;41:180-185.
20. Castellares C, Barreiro P, Martin-Carbonero L, et al. Liver cirrhosis in HIV-infected patients: Prevalence, aetiology and clinical outcome. J Viral Hepat 2008;15:165-172. (Pubitemid 351143738)
21. Pineda JA, González J, Ortega E, et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2010;17:714-719.
22. Pineda JA, Romero-Gómez M, D?́az-Garc?́a F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005:41: 779-789. (Pubitemid 40462940)
23. Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20:49-57. (Pubitemid 41818114)
24. QurishiN,Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-1713. (Pubitemid 37468321)
25. Bonacini M, Louie S, Bzowej N, et al. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004;18:2039-2045. (Pubitemid 39463357)
26. Peng JZ, Pulido F, Causemaker SJK, et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol 2006;46: 265-274. (Pubitemid 43260313)
27. Barreiro P, Rodr?́guez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007;195:973-978.
28. Meynard JL, Lacombe K, Poirier JM, et al. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. J Antimicrob Chemother 2009;63:579-584.
29. Castera L. Transient elastography and other non-invasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-314.
30. Castera L, Sebastiani G, Le Bail B, et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010;52:191-198.